High-stakes decisions rarely present as a clear choice between moving forward and holding back. More often, both paths carry visible downside.
Acting introduces financial exposure, execution risk, and the possibility of being wrong in public. Waiting preserves optionality, but it also consumes time, weakens momentum, and delays learning. The tension is not between risk and safety. It is between two different forms of risk.
Yi-Kai Lo faced that tension while leading Aneuvo through a critical clinical trial. The company chose to launch before receiving full FDA clarity. Months later, it chose to pause that same trial when product quality issues surfaced.
Those decisions move in opposite directions. One accelerates under uncertainty. The other halts progress under pressure. Taken together, they clarify a more demanding standard for CEO judgment: the ability to determine when delay has become more damaging than action—and when action has become more damaging than delay.
The context matters. Aneuvo is developing a bioelectronic medical device in an environment where regulatory approval, clinical validation, and product performance are tightly linked. Decisions are not easily reversible, and mistakes are measured in years and millions of dollars.
The company spent 11 months in discussion with the FDA to refine its clinical trial design. That duration reflects the novelty of the work. It also creates a structural problem for a small company. Extended waiting affects capital efficiency, team focus, and the ability to maintain forward motion.
The cost of the trial itself made the stakes explicit. Yi-Kai described it directly: “This study cost us like seven to eight million dollars.” The timeline was equally significant. A misstep could “easily waste two years and waste lot of money.”
Those are the risks of acting. They are concrete, measurable, and easy for a team to focus on. The harder task is identifying what continued waiting is costing in parallel.
The turning point in Aneuvo’s decision came from reframing the discussion. The team already understood the risks and potential benefits of launching. What had not been fully surfaced was the cost of waiting.
Yi-Kai described the alignment point: “After analyzing the risk and benefit, right, and also the cost of keep delaying the study,” the team moved forward.
That additional variable changes the decision. Without it, waiting appears disciplined. With it, waiting becomes a tradeoff that can be compared directly against action.
In this case, further delay was no longer producing enough additional clarity to justify the time it consumed. The company had already engaged extensively with the FDA. It understood the design well enough to proceed, even without final confirmation.
Aneuvo launched the study. Two weeks later, the FDA approval followed. The outcome reinforces the decision, but it does not define it. The reasoning was already complete before certainty arrived.
For a scaling CEO, this is the practical standard: act when additional information is unlikely to change the decision enough to justify the delay required to obtain it.
The team was not immediately aligned. Some members wanted more certainty before committing. Their position was grounded in real risk: capital, time, and regulatory uncertainty.
Alignment did not come from asserting urgency. It came from expanding the frame of the decision.
When both the cost of action and the cost of delay are visible, the team can evaluate the tradeoff rather than argue from different assumptions. The decision becomes a comparison, not a debate over posture.
This is especially important in technical and regulated environments where expertise is distributed. Engineers, clinicians, and regulatory advisors each see different aspects of the risk. The CEO’s role is to integrate those perspectives into a complete picture.
Once the decision is made, alignment must extend beyond the internal team. Aneuvo coordinated with clinical principal investigators across multiple research centers. The decision created commitments that others had to plan around. Execution depended on turning internal alignment into external coordination.
The second decision tested a different dimension of leadership.
After six months of execution, Aneuvo began receiving repeated complaints from clinical sites about electrode quality. The issue affected the delivery of stimulation, which meant the treatment could fail to produce meaningful results.
Yi-Kai described the moment: “all of a sudden, we got product issues.”
At this stage, the pressure favors continuation. The trial is underway. Time has been invested. Pausing disrupts progress and introduces delay after the company has already worked to avoid it.
Yet continuing with a known flaw would have compromised the outcome. In Yi-Kai’s words, it would be “throwing the money into the water.”
The company chose to pause recruitment for approximately six months while it addressed the issue. Patients already in the trial continued, but new enrollment stopped.
This decision applies the same logic as the first, but in reverse. The company again compared two costs: the cost of delay versus the cost of continuing flawed execution. In this case, continuing had become the more damaging path.
This is where decisiveness becomes more demanding. Moving forward under uncertainty is one form of commitment. Stopping after momentum exists requires a different kind of discipline.
Pausing the study created immediate implications for clinical partners. Investigators needed to understand what had changed, how the company would respond, and when the study would resume.
Yi-Kai’s approach was direct: “we have to be transparent.”
Transparency in this context is operational. It involves explaining the issue, outlining the response, and providing a timeline that others can plan against. It is not about framing the situation favorably. It is about maintaining coordination and trust.
Aneuvo had to ensure that clinical partners could continue to engage with the study once it resumed. That required clarity, not reassurance.
For a CEO, the decision does not end with the internal conclusion. It extends into how the decision is communicated to those who must act on it. Poor communication can undermine a sound decision. Clear communication reinforces it.
The electrode problem led to a broader set of insights. Yi-Kai noted that the issue was not isolated. It involved multiple contributing factors, including vendor selection, design considerations, and process decisions.
Addressing the problem required changes across hardware, software, and manufacturing. It also informed how the company approached vendor relationships going forward.
This pattern is common in scaling companies. A product failure often reveals weaknesses in the broader system: how vendors are selected, how quality is monitored, how teams are structured, and how decisions are escalated.
Yi-Kai connected this to a leadership principle that guided his thinking: “I have to build the right team at the right stage.”
In this context, team composition is directly tied to decision quality. The ability to identify risk early, evaluate tradeoffs accurately, and execute corrective action depends on having the right capabilities in place. The team shapes what the CEO can see and how effectively the company can respond.
Across both decisions, a consistent pattern emerges. The CEO is not choosing between speed and caution as fixed positions. The CEO is continually repricing the decision as new information appears.
Before launch, the question was whether additional FDA clarity justified further delay. After extended engagement, the answer was no. The cost of waiting had overtaken the remaining uncertainty.
After launch, the question shifted. Once product quality issues emerged, the cost of continuing outweighed the cost of pausing. The company adjusted accordingly.
In both cases, the decision was made without full certainty. In both cases, the company accepted a form of cost. What changed was the relative weight of each option as conditions evolved.
This is the core discipline. The CEO must:
Yi-Kai’s experience shows that these are not abstract principles. They are applied in moments where the consequences are immediate and material.
A scaling CEO is often caught between two incomplete views. One emphasizes caution and the avoidance of visible mistakes. The other emphasizes speed and the need to maintain momentum.
Neither is sufficient on its own.
The more useful approach is to treat delay and action as competing costs that must be evaluated explicitly. Waiting is not neutral. Acting is not inherently aggressive. Each has consequences that can be compared.
Yi-Kai Lo’s decisions illustrate how that comparison evolves over time. He moved forward when delay became the larger risk. He paused when continuation threatened the validity of the outcome. He maintained alignment by making the tradeoffs visible. He sustained execution by communicating clearly with stakeholders. He improved future decisions by addressing the underlying causes revealed by the problem.
For CEOs facing similar moments, the question is not whether to move or wait. The question is whether the cost of each path has been defined clearly enough to decide with discipline—and whether that evaluation is being updated as the situation changes.
Yi-Kai Lo is the CEO of Aneuvo, a bioelectronic medicine company developing medical products that use electrical stimulation to treat injuries and diseases not addressed by conventional approaches. He has led the company through FDA approval, clinical trials, product quality challenges, and commercialization planning.
__________
Jeff Holman is a CEO advisor, legal strategist, and founder of Intellectual Strategies. With years of experience guiding leaders through complex business and legal challenges, Jeff equips CEOs to scale with confidence by blending legal expertise with strategic foresight. Connect with him on LinkedIn.
Intellectual Strategies provides innovative legal solutions for CEOs and founders through its fractional legal team model. By offering proactive, integrated legal support at predictable costs, the firm helps leaders protect their businesses, manage risk, and focus on growth with confidence.
__________
The Breakout CEO podcast brings you inside the pivotal moments of scaling leaders. Each week, host Jeff Holman spotlights breakout stories of scaling CEOs—showing how resilience, insight, and strategy create pivotal inflection points and lasting growth.
Listen and subscribe on your favorite podcast platform:
__________
Want to be a guest—or know a scaling CEO with a breakout story to share? Apply directly at go.intellectualstrategies.com.
